



LETTER OF INTENT
Brain Health: Sleep 2023 Program

DEADLINE: July 11, 2023, 2:00pm ET

Applicants will be notified of Proposal invitations in October 2023.

Applicants may receive questions from the review committee (via Foundation staff) by September 7, 2023. Responses must be submitted by end of day September 12, 2023.

This Letter of Intent is an example only. Do not complete this paper application.
Please submit the Letter of Intent online through the Foundation's grant management system. Please visit our [program webpage](#) for more details.

Application Number:

Principal Applicant:

Project Title:

Applicant Details

Team Members	Organizations	Primary Contact Information	Role in Project	Estimated Time Spent on Project
1. Salutation:	Primary Organization:	Address:	<input type="checkbox"/> Principal Applicant	%
First Name:	Position Title:	Phone:	<input type="checkbox"/> Co-Applicant	
Last Name:	Other Affiliations/ Position Titles:	Email:	<input type="checkbox"/> Collaborator	
2. Salutation:	Primary Organization:	Address:	<input type="checkbox"/> Principal Applicant	%
First Name:	Position Title:	Phone:	<input type="checkbox"/> Co-Applicant	
Last Name:	Other Affiliations/ Position Title:	Email:	<input type="checkbox"/> Collaborator	

Note: Projects are not limited to two team members as laid out on this sample application form; projects may include as many team members as needed for the successful execution of the project.

Application Overview

1. Keywords to describe the proposed work

2. In 1-2 sentences, describe what sleep-based strategy is being evaluated to improve brain-related outcome measures relevant to neurodegenerative diseases of aging. (*maximum 60 words*)

3. Research will have a significant impact in which neurodegenerative disease(s) of aging?

(*Select only those that apply. There is no benefit to selecting more diseases.*)

- | | |
|---|--|
| <input type="checkbox"/> Alzheimer's disease | <input type="checkbox"/> Vascular contributions to the listed diseases (not stroke-mediated vascular disease) |
| <input type="checkbox"/> Dementia with Lewy bodies | <input type="checkbox"/> Prodromes to the listed diseases (please also check the disease(s) to which your condition is a prodrome) |
| <input type="checkbox"/> Frontotemporal dementia | |
| <input type="checkbox"/> Multiple system atrophy | |
| <input type="checkbox"/> Parkinson's disease | |
| <input type="checkbox"/> Progressive supranuclear palsy | |

4. Have you applied to the Weston Family Foundation (which includes the Weston Brain Institute) previously with *similar* proposed work? If so, specify the previous LOI title and program applied to. Please briefly explain how this LOI is different than the previously submitted work. Yes *Please specify:*
 No
(*This information will not be used to assess the application.*)

5. Have you applied to other funding agencies with the same proposed work? Yes *Please specify:*
(*This information will not be used to assess the application.*) No

6. Is this your first time applying for a grant from the Weston Family Foundation (which includes the Weston Brain Institute)? Yes
(*This information will not be used to assess the application.*) No

7. Is this your first application for a research grant specifically in the area of neurodegenerative diseases of aging? Yes
(*This information will not be used to assess the application.*) No

The adjudication committee for this program does not include researchers based in Canada. Please list the full names of any individuals located outside of Canada who are competitive with you and therefore should not review your application. Please do not exclude reviewers for other reasons as we are unable to honour those requests. Type "None" if you have no reviewer exclusion.
(*This information will not be used to assess the application.*)

Project Information

Before completing the project information requested below, please refer to the following sections in the Program Details document:

“Section 1: Scope and other Project Considerations”, “Section 4: Review Criteria”, and “Section 6: Expected Project Outcomes”.

1. Central hypothesis, goals and specific aims.

Aims should complement each other and address the stated goals and hypothesis(es). (*maximum 350 words*)

2. Novelty, significance, and impact: Clarify the innovative aspect of the project and how this project is different than what is currently studied. Why is it important that the proposed work be carried out (i.e., how would the results advance the research and development of sleep-based interventions that improve brain-related outcome measures relevant to (or associated with) neurodegenerative diseases of aging in Canada?) What populations or sub-populations in Canada will benefit from the research study? (*maximum 350 words*)

3. Experimental approach: Please outline how the proposed work will be carried out and interpreted, including clear go/no-go criteria, and whether the selected cohort is reflective of the population in Canada. Please do not include background information (e.g., pathology, etiology or incidence/prevalence) of neurodegenerative diseases of aging. (*maximum 1300 words*)

4. Knowledge mobilization (KM) plan:

A. Please outline the path to impact (KM plan) required for the results of this study to achieve meaningful and clinical/real-world impact for the end users that will ultimately benefit from the study. In the plan, please indicate the necessary milestones (e.g., experimental, regulatory, financial, commercial, or implementation) that would need to be achieved for the impact to be realized. Include approximate timelines for each anticipated milestone.

Note: The milestones under the KM plan are what is envisioned for future development and are not meant to be completed as part of the current application.

B. Please list all relevant and interested parties that could help facilitate this KM plan. Indicate if, and the extent to which, you have already engaged with any of these parties regarding 1) the relevance of your proposed study and 2) the feasibility or accuracy of this plan. If you have not yet engaged with any of these parties, please indicate what interested party you would prioritize and when you plan to engage with them. (*maximum 200 words*)

4. Preliminary data: A maximum of 1 page of preliminary data that best supports the application is required and can be uploaded as a PDF file, e.g., figures or tables.

List of publications cited in the application: Please include full citations with a complete author list and PMID.
